136 related articles for article (PubMed ID: 22101248)
41. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
42. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
43. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
44. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Loeffler-Ragg J; Mueller D; Gamerith G; Auer T; Skvortsov S; Sarg B; Skvortsova I; Schmitz KJ; Martin HJ; Krugmann J; Alakus H; Maser E; Menzel J; Hilbe W; Lindner H; Schmid KW; Zwierzina H
Mol Cancer Ther; 2009 Jul; 8(7):1995-2006. PubMed ID: 19567817
[TBL] [Abstract][Full Text] [Related]
45. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
[TBL] [Abstract][Full Text] [Related]
46. Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.
Chen XW; Liu WT; Wang YX; Chen WJ; Li HY; Chen YH; Du XY; Peng FF; Zhou WD; Xu ZZ; Long HB
J Diabetes Complications; 2016 Jul; 30(5):760-9. PubMed ID: 27052152
[TBL] [Abstract][Full Text] [Related]
47. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE
Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742
[TBL] [Abstract][Full Text] [Related]
48. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
[TBL] [Abstract][Full Text] [Related]
49. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
[TBL] [Abstract][Full Text] [Related]
50. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Teraishi F; Guo W; Zhang L; Dong F; Davis JJ; Sasazuki T; Shirasawa S; Liu J; Fang B
Cancer Res; 2006 Jun; 66(12):6072-9. PubMed ID: 16778179
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
52. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
53. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Codony-Servat J; Tapia MA; Bosch M; Oliva C; Domingo-Domenech J; Mellado B; Rolfe M; Ross JS; Gascon P; Rovira A; Albanell J
Mol Cancer Ther; 2006 Mar; 5(3):665-75. PubMed ID: 16546981
[TBL] [Abstract][Full Text] [Related]
54. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
55. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
56. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
[TBL] [Abstract][Full Text] [Related]
57. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
Komatsu S; Miyazawa K; Moriya S; Takase A; Naito M; Inazu M; Kohno N; Itoh M; Tomoda A
Int J Oncol; 2012 Apr; 40(4):1029-39. PubMed ID: 22200786
[TBL] [Abstract][Full Text] [Related]
58. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
60. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
